Regarding the commercial license for ChimeraX

[m-mima@…]

To whom it may concern,

My name is Masashi Mima at Taisho Pharmaceutical ( Japanese pharmaceutical company ).

Let me ask you a question regarding the commercial license for ChimeraX.

If a university uses ChimeraX in collaborative research with a pharmaceutical company,
does the university need to obtain a commercial license?

I look forward to hearing from you.

Sincerely yours,

---------------------------------------------------
Masashi Mima

Taisho Pharmaceutical Co., Ltd.

[Eric Pettersen]

Forwarded onto licensing email address

[m-mima@…]

Dear Elaine,

I'm resending the email that I sent you the other day, just in case you missed it.

Thank you for your reply.

Just to be sure, please find below additional information regarding our collaborative research.
- Nobody in the pharmaceutical company will be using ChimeraX.
- Only person affiliated with the university will be using ChimeraX within its facilities.
- The structural analysis results obtained using ChimeraX will be published for the purpose of promoting our pharmaceutical products.

Am I correct in understanding that even in this case, the university would not need to get a commercial license?

Sincerely yours,

---------------------------------------------------
Masashi Mima

Taisho Pharmaceutical Co., Ltd.

-----Original Message-----
From: Elaine Meng <meng@cgl.ucsf.edu> 
Sent: Thursday, December 28, 2023 2:57 AM
To: \u7f8e\u99ac\u3000\u5c06\u53f8 <m-mima@taisho.co.jp>
Cc: chimera test uid <chimera@cgl.ucsf.edu>
Subject: Re: Regarding the commercial license for ChimeraX

CAUTION ! This email is sent by an EXTERNAL SENDER.
- Do not click links or open attachments unless you trust the sender and know the content is safe.



Dear Masashi Mima,
The university would not need to get a commercial license to use ChimeraX for its collaboration with the company.

However, if anybody in the pharmaceutical company will be using ChimeraX, the pharmaceutical company needs to get a commercial license.

Regards,
Elaine
-----
Elaine C. Meng, Ph.D.
UCSF Chimera(X) team
Resource for Biocomputing, Visualization, and Informatics Department of Pharmaceutical Chemistry University of California, San Francisco


>
>
>
>
>
>
>
>
>

[m-mima@…]

Dear Elaine,

I apologize for contacting you repeatedly.
Just to be sure, could you please confirm the following again?

In the case of our collaboration, the software will be used only at the university's facilities, so the pharmaceutical company and the university do not need to get a commercial license.
Is that correct?

Sincerely yours,

---------------------------------------------------
Masashi Mima

Taisho Pharmaceutical Co., Ltd.

-----Original Message-----
From: Elaine Meng <meng@cgl.ucsf.edu> 
Sent: Thursday, January 18, 2024 1:46 AM
To: \u7f8e\u99ac\u3000\u5c06\u53f8 <m-mima@taisho.co.jp>
Cc: chimera test uid <chimera@cgl.ucsf.edu>
Subject: Re: Regarding the commercial license for ChimeraX

CAUTION ! This email is sent by an EXTERNAL SENDER.
- Do not click links or open attachments unless you trust the sender and know the content is safe.



Please do not send messages to chimerax-bugs@cgl.ucsf.edu unless it is about a ChimeraX bug.  These messages about licensing should be sent to chimera@cgl.ucsf.edu only.

Yes, I did see that message and responded many days ago, but when editing the email addresses to eliminate "chimerax-bugs" I failed to include your email address.  Sorry about that.  Please see below:

>
>
>
>
>
>
>> Begin forwarded message:
>>
>> From: \u7f8e\u99ac\u3000\u5c06\u53f8 <m-mima@taisho.co.jp>
>> Subject: RE: Regarding the commercial license for ChimeraX
>> Date: January 11, 2024 at 5:06:07 PM PST
>> To: chimera test uid <chimera@cgl.ucsf.edu>
>>
>> Dear Elaine,
>>
>> Thank you for your reply.
>>
>> Just to be sure, please find below additional information regarding our collaborative research.
>> - Nobody in the pharmaceutical company will be using ChimeraX.
>> - Only person affiliated with the university will be using ChimeraX within its facilities.
>> - The structural analysis results obtained using ChimeraX will be published for the purpose of promoting our pharmaceutical products.
>>
>> Am I correct in understanding that even in this case, the university would not need to get a commercial license?
>>
>> Sincerely yours,
>>
>> ---------------------------------------------------
>> Masashi Mima
>>
>> Taisho Pharmaceutical Co., Ltd.

>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>> Begin forwarded message:
>>
>> From: \u7f8e\u99ac\u3000\u5c06\u53f8 <m-mima@taisho.co.jp>
>> Subject: Regarding the commercial license for ChimeraX
>> Date: December 26, 2023 at 11:06:19 PM PST
>> To: "chimerax-bugs@cgl.ucsf.edu" <chimerax-bugs@cgl.ucsf.edu>
>>
>> To whom it may concern,
>>
>> My name is Masashi Mima at Taisho Pharmaceutical ( Japanese pharmaceutical company ).
>>
>> Let me ask you a question regarding the commercial license for ChimeraX.
>>
>> If a university uses ChimeraX in collaborative research with a 
>> pharmaceutical company, does the university need to obtain a commercial license?
>>
>> I look forward to hearing from you.
>>
>> Sincerely yours,
>>
>> ---------------------------------------------------
>> Masashi Mima
>>
>> Taisho Pharmaceutical Co., Ltd.
>
>
>